Evidence map›Paper›PMID 40144472›Full record

ArticleLiver cancer2025

Assessment of Macrovascular Invasion in Advanced Hepatocellular Carcinoma: Clinical Implications and Treatment Outcomes with Systemic Therapy.

Masanori Inoue, Sadahisa Ogasawara, Kazufumi Kobayashi, Tomomi Okubo, Norio Itokawa, Masamichi Obu, Kentaro Fujimoto, Hidemi Unozawa, Sae Yumita, Kisako Fujiwara and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Masanori InoueDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Sadahisa OgasawaraDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Kazufumi KobayashiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Tomomi OkuboDepartment of Gastroenterology, Nippon Medical School Chibahokusoh Hospital, Chiba, Japan.
Norio ItokawaDepartment of Gastroenterology, Nippon Medical School Chibahokusoh Hospital, Chiba, Japan.
Masamichi ObuDepartment of Gastroenterology, Kimitsu Chuo Hospital, Chiba, Japan.
Kentaro FujimotoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hidemi UnozawaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Sae YumitaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Kisako FujiwaraDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Miyuki NakagawaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hiroaki KanzakiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Keisuke KorokiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Soichiro KiyonoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Masato NakamuraDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Naoya KanogawaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takayuki KondoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Shingo NakamotoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Kengo NagashimaClinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.
Ei ItobayashiDepartment of Gastroenterology, Asahi General Hospital, Chiba, Japan.
Masanori AtsukawaDepartment of Gastroenterology, Nippon Medical School Chibahokusoh Hospital, Chiba, Japan.
Yoshihiro KomaDepartment of Gastroenterology, Kimitsu Chuo Hospital, Chiba, Japan.
Ryosaku AzemotoDepartment of Gastroenterology, Kimitsu Chuo Hospital, Chiba, Japan.
Naoya KatoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Macrovascular invasion (MVI) is a strong prognostic factor for advanced hepatocellular carcinoma (HCC). The current criteria for radiological assessment are unclear in evaluating the impact of MVI on systemic therapy. In this study, we standardized the assessment of MVI and validated its clinical relevance. Methods: Clinical data were collected from patients with advanced HCC and MVI who received first-line systemic therapy at four medical centers in Japan. First, we used MVI progressive disease (MVI-PD) to track MVI progression and Response Evaluation Criteria in Solid Tumors version 1.1 progressive disease (RECIST v1.1-PD) to evaluate tumor enlargement other than MVI and the appearance of new lesions. Next, we assessed the prognostic value of MVI-PD and RECIST v1.1-PD. Results: Of the 207 advanced HCC patients with MVI, 189 received appropriate imaging evaluation. Forty (21.2%) patients had MVI-PD and RECIST v1.1-PD, 51 (27.0%) had prior MVI-PD, and 61 (32.3%) had prior RECIST v1.1-PD. In a landmark analysis, the prognosis of 163 patients who survived more than 3 months was analyzed based on the assessment of imaging response during the first 3 months. The median overall survival (OS) was 5.4 months in those who had MVI-PD and RECIST v1.1-PD, 7.4 months in those who had RECIST v1.1-PD only, 7.2 months in those who had MVI-PD only, and 19.7 months in patients who had neither ( Conclusion: Our findings demonstrate the link between MVI progression and poor OS in systemic therapy for advanced HCC, emphasizing the importance of an accurate method for assessing MVI progression.

Indexed as

Drug therapyHepatic vein tumor thrombosisHepatocellular carcinomaPortal vein tumor thrombosisResponse Evaluation Criteria in Solid Tumors

Identifiers

PMID40144472
PMCPMC11936442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.